Stanford, CA – April 24, 2024 – In a discovery poised to fundamentally reshape our understanding of cancer immunology and open new therapeutic frontiers, scientists have unearthed a surprising, critical role for a protein identified nearly four decades ago. Erythropoietin (EPO), long celebrated for its ability to stimulate red blood cell production, has now been found to act as a powerful dampener of the immune system’s response to cancer. This groundbreaking research, published today in the prestigious journal Science, reveals that blocking EPO’s activity can transform previously "cold," immune-resistant tumors into "hot" immunological battlegrounds, teeming with cancer-fighting immune cells.
The implications of this finding are profound. When combined with existing immunotherapies, this novel approach led to the complete regression of established liver tumors in the majority of mice tested, with treated animals living for the entire duration of the experiment. In stark contrast, control animals succumbed to the disease within weeks. This research offers a beacon of hope for patients with cancers currently unresponsive to the revolutionary class of immune checkpoint inhibitors.
"This is a fundamental breakthrough in our understanding of how the immune system is turned off and on in cancer," exclaimed Dr. Edgar Engleman, MD, PhD, a professor of pathology and medicine at Stanford University, and senior author of the study. His palpable excitement underscores the significance of the discovery. "I could not be more excited about this discovery, and I hope treatments that target the mechanism we uncovered will quickly move forward to human trials."
Leading the meticulous experimental work was Dr. David Kung-Chun Chiu, PhD, a basic life research scientist and lead author of the study. Their collaborative effort has not only illuminated a previously hidden facet of cancer biology but also repurposed a familiar molecule into a formidable new target in the arsenal against the disease.
Main Facts: EPO’s Dual Identity Unveiled
The central revelation of this study is the astonishing discovery that erythropoietin (EPO), a hormone primarily known for its role in stimulating red blood cell production, is a critical immunosuppressive factor in the tumor microenvironment. Identified nearly 40 years ago for its hematopoietic properties, EPO has historically been administered to patients suffering from anemia, including those undergoing cancer treatment. However, a troubling side effect emerged over a decade ago: EPO administration in anemic cancer patients appeared to accelerate tumor growth, a connection so concerning that the U.S. Food and Drug Administration (FDA) issued a black box warning on EPO-stimulating agents in 2007, cautioning against their use in individuals with cancer.
Despite this ominous clinical observation, the precise mechanism linking EPO to tumor progression remained elusive. The prevailing scientific consensus continued to pigeonhole EPO as solely a red blood cell growth factor. The Stanford team, however, meticulously demonstrated that EPO plays a direct and pivotal role in orchestrating immune evasion by tumors.
Their research specifically focused on liver cancer models in mice, a disease often characterized by "cold" tumors – those with a sparse infiltration of immune cells and a poor response to standard immunotherapies. By blocking the activity of EPO, either by preventing its production within tumor cells or by inhibiting its receptor on specific immune cells, the researchers observed a dramatic transformation. These previously "cold" tumors became "hot," actively recruiting and activating a robust army of cancer-fighting immune cells, particularly T cells.
The true power of this discovery was demonstrated when this EPO-blocking strategy was combined with an anti-PD-1 immunotherapy. Anti-PD-1 therapies, like Keytruda, work by releasing the brakes on T cells, allowing them to attack cancer more effectively. While often ineffective against "cold" tumors due to the lack of T cells, the EPO blockade provided the necessary immune cell infiltration. The combination therapy resulted in complete and sustained regression of existing liver tumors in most mice, a monumental achievement that offers a compelling blueprint for future human trials. The treated animals not only saw their tumors vanish but also lived for the entire duration of the experimental period, a stark contrast to the rapid progression and demise observed in control groups.
Chronology: From Hematopoiesis to Immunosuppression – EPO’s Evolving Narrative
The story of erythropoietin is one of scientific evolution, from a clear understanding of its primary function to the gradual uncovering of its more complex and, at times, paradoxical roles.
Early Identification and Primary Role (Circa 1980s): EPO was first identified as the hormone responsible for regulating erythropoiesis, the process of red blood cell production. Its utility in treating anemia, particularly in patients with kidney disease or those undergoing chemotherapy, quickly made it a cornerstone of hematological medicine. For decades, its biological function was largely confined to this hematopoietic role, cementing its image as a benign, beneficial growth factor.
The Troubling Link to Cancer Progression (Early 2000s & 2007 FDA Warning): The first cracks in EPO’s benign image appeared in the early 2000s. Clinical trials investigating the use of EPO-stimulating agents in anemic cancer patients began to yield disturbing results. Studies indicated that patients receiving EPO for chemotherapy-induced anemia experienced accelerated tumor growth and, in some cases, poorer overall survival. This unexpected correlation prompted the FDA to mandate a "black box" warning label on EPO-stimulating drugs in 2007, a severe cautionary measure indicating potential adverse effects. Researchers observed a clear link between higher levels of naturally occurring EPO and its receptor (EPOR) in tumors and worse patient prognoses. As Dr. Engleman recounts, "Those old reports showed clearly that the more EPO or EPOR there was in tumors, the worse off the patients were." Yet, despite these strong epidemiological and clinical signals, the precise biological link – particularly to cancer immunity – remained elusive. The scientific community struggled to reconcile EPO’s established role as a red blood cell stimulant with its apparent pro-tumorigenic effects. "The connection between EPO and cancer immunity was never made until now. In fact, it took a long time and a lot of experiments to convince us that EPO plays a fundamental role in blocking the immune response to cancer, because EPO is so well established as a red blood cell growth factor," Engleman noted, highlighting the entrenched scientific dogma they had to overcome.
The Genesis of the Current Research (Dr. Chiu’s Mouse Models): The current breakthrough began with the meticulous work of Dr. David Kung-Chun Chiu, who developed sophisticated genome-editing techniques to create a diverse array of mouse models for liver cancer. These models were designed to precisely recapitulate the specific genetic mutations, histological features, and responses to approved therapies observed in various human liver cancer subtypes. Tumor formation was initiated either by injecting DNA encoding liver cancer-associated proteins into the animals’ tail veins or by directly implanting liver cancer cells into their livers. This careful modeling provided the robust experimental platform necessary to dissect the intricate interplay between cancer cells and the immune system.
Investigating Immunotherapy Resistance (PD-1 Blockade): The research team was particularly interested in understanding why many cancers, including the vast majority of liver, pancreas, colon, breast, and prostate cancers, remain resistant to anti-PD-1 immunotherapies. These therapies, which include commercially available drugs like Keytruda, have revolutionized the treatment of cancers such as melanoma, Hodgkin’s lymphoma, and certain lung cancers by activating T cells to attack tumors. However, their efficacy is limited in tumors characterized as "cold" – those lacking significant immune cell infiltration.
The "Cold" vs. "Hot" Tumor Observation: In their mouse models, the researchers observed precisely what is seen in human liver cancers. Some combinations of genetic mutations led to the development of "cold" liver tumors that were largely ignored by the immune system. These tumors did not shrink when treated with anti-PD-1, primarily because few T cells were present within the tumor microenvironment to be activated. Conversely, other mutations resulted in "hot" or "inflamed" tumors, replete with T cells, which were highly sensitive to anti-PD-1 treatment and exhibited significant regression.
The Unexpected EPO Link and Hypoxia: It was during this phase that the pivotal, unexpected observation emerged: the "cold" tumors displayed significantly elevated levels of EPO compared to their "hot" counterparts. The researchers hypothesized that this increase was likely a consequence of hypoxia – the oxygen-poor microenvironment prevalent in rapidly growing, poorly vascularized tumors. Hypoxia is known to induce cancer cells to produce various proteins, including EPO, in an attempt to stimulate red blood cell formation and thus increase oxygen delivery. However, as Dr. Engleman candidly admitted, "Hypoxia in tumors has been studied for decades. It just didn’t dawn on anyone, including me, that EPO could be doing anything in this context other than serving as a red blood cell growth factor." This long-held assumption was about to be dramatically overturned.
The Pivotal Manipulation Experiments: Driven by curiosity, the team first confirmed the human correlation by consulting existing databases, which showed a clear link between elevated EPO levels and poorer survival in patients with cancers of the liver, kidney, breast, colon, and skin. Then came the critical experiments: they genetically tinkered with the tumor cells’ ability to produce EPO. The results were astounding. Mutations that had previously led to "cold" tumors instead resulted in "hot" tumors when those tumor cells were modified to be incapable of producing EPO. Conversely, "hot" tumors that had previously been successfully eradicated by the immune system thrived and grew unchecked when engineered to produce elevated levels of EPO. This direct cause-and-effect relationship was the smoking gun.
Unveiling the Immunosuppressive Mechanism: The researchers then embarked on exhaustive studies to unravel the precise mechanism. They discovered that in "cold" tumors, the tumor cells themselves produce and secrete EPO. This secreted EPO then binds to specific receptors (EPOR) located on the surface of immune cells called macrophages within the tumor microenvironment. Upon binding, EPO triggers a phenotypic switch in these macrophages, skewing them towards an immunosuppressive role. These reprogrammed macrophages then actively "shoo away" cancer-killing T cells, preventing their infiltration into the tumor, and simultaneously dampen the activity of any T cells that do manage to enter. This EPO-mediated crosstalk between tumor cells and macrophages effectively creates an "immune desert," protecting the tumor from attack.
The Triumph of Combination Therapy: The culmination of this chronological journey was the investigation into the combinatorial effect of simultaneously blocking the EPO signaling pathway and the anti-PD-1 pathway. The results were unequivocal and dramatic. In mice with "cold" liver tumors, those treated with a control substance or anti-PD-1 alone did not survive beyond eight weeks post-tumor induction. However, 40% of mice whose macrophages were genetically unable to express the EPO receptor lived for 18 weeks, the full duration of the experiment. The most striking outcome occurred when anti-PD-1 treatment was administered to mice lacking the EPO receptor: all animals lived for the entire experimental period, with complete tumor regression. "It’s simple," Dr. Engleman summarized. "If you remove this EPO signaling, either by lowering the hormone levels or by blocking the receptors on the macrophages, you don’t just get a reduction in tumor growth, you get tumor regression along with sensitivity to anti-PD-1 treatment."
Supporting Data: Deep Dive into the Mechanism and Clinical Relevance
The groundbreaking findings are underpinned by a wealth of supporting data that meticulously detail the cellular and molecular mechanisms at play, while also strongly indicating the clinical relevance to human cancers.
The "Cold" vs. "Hot" Tumor Paradigm: The distinction between "cold" and "hot" tumors is a cornerstone of modern cancer immunology. "Hot" tumors are characterized by significant infiltration of immune cells, particularly cytotoxic T lymphocytes (CTLs), and often respond well to immune checkpoint inhibitors. "Cold" tumors, conversely, lack this immune cell infiltration, forming an "immune desert" that renders them resistant to therapies that rely on activating existing T cells. The Stanford research provides a novel mechanism by which tumors create and maintain this "cold" phenotype. Their mouse models accurately mirrored this clinical reality, with some tumor genotypes consistently yielding "cold" tumors unresponsive to PD-1 blockade, while others produced "hot" tumors that were sensitive.
Hypoxia as the Inducer: A critical piece of the puzzle is the role of hypoxia within the tumor microenvironment. Rapidly growing tumors often outpace their blood supply, leading to regions of low oxygen. This hypoxic stress is a well-known driver of tumor progression, influencing metabolism, angiogenesis, and resistance to therapy. The study demonstrates that hypoxia directly stimulates cancer cells to produce and secrete EPO. This is a crucial link, explaining why EPO levels are elevated in aggressive, immune-resistant tumors. The tumor, in its desperate attempt to acquire oxygen, inadvertently produces a powerful immunosuppressive signal.
Macrophages: The Orchestrators of Immunosuppression: The research precisely identifies macrophages as the key immune cells responding to tumor-derived EPO. Macrophages are highly plastic immune cells, capable of adopting diverse functional states. They can be anti-tumorigenic (often termed M1-like) or pro-tumorigenic and immunosuppressive (M2-like). The study revealed that EPO secreted by tumor cells binds to erythropoietin receptors (EPOR) predominantly expressed on macrophages within the tumor microenvironment. This binding event triggers a cascade of intracellular signaling that reprograms the macrophages, skewing them towards an M2-like, immunosuppressive phenotype. These reprogrammed macrophages then become central to creating an immune-privileged environment for the tumor.
T-Cell Exclusion and Dampening: The immunosuppressive macrophages, under EPO’s influence, actively prevent the infiltration of T cells into the tumor core. They secrete factors that physically exclude T cells and also directly inhibit the activity of any T cells that manage to breach the tumor’s defenses. This mechanism explains why "cold" tumors lack T-cell infiltration, rendering anti-PD-1 therapies ineffective, as there are simply no T cells to unleash. By blocking EPO signaling, the researchers effectively reversed this macrophage-mediated T-cell exclusion, allowing T cells to flood the tumor and mount an effective anti-cancer response.
The Strength of Pre-existing Human Data: A compelling aspect of this study is its strong correlation with previously observed, yet unexplained, human clinical data. The researchers leveraged existing databases to confirm that elevated levels of EPO and its receptor (EPOR) are indeed consistently correlated with poorer survival across a range of human cancers, including liver, kidney, breast, colon, and skin. This pre-existing correlation, which previously lacked a mechanistic explanation regarding immunity, now finds a robust biological basis in the EPO-macrophage-T-cell axis. This provides powerful translational evidence, suggesting that the mechanisms observed in mice are highly likely to be conserved and clinically relevant in human patients.
Robust Experimental Design: The credibility of the findings is further bolstered by the rigorous experimental design, including the creation of diverse liver cancer mouse models that accurately reflect human disease heterogeneity. The ability to switch tumors from "cold" to "hot" by simply manipulating EPO production, and vice versa, provides definitive proof of causation. Furthermore, the genetic ablation of EPOR specifically on macrophages demonstrated the precise cellular target of EPO’s immunosuppressive action. The complete and sustained tumor regression observed with the combination therapy represents a statistically significant and clinically impactful outcome, far exceeding the modest responses often seen in monotherapy or control arms.
Official Responses: From Cautionary Warnings to Hopeful Projections
The official responses to EPO’s role in cancer have evolved dramatically over time, mirroring the progression of scientific understanding.
The 2007 FDA Black Box Warning: The most significant "official response" to EPO’s interaction with cancer prior to this study came from the U.S. Food and Drug Administration. In 2007, based on accumulating clinical trial data suggesting that EPO-stimulating agents could accelerate tumor growth and worsen patient outcomes in anemic cancer patients, the FDA mandated a "black box" warning on these drugs. This was a critical regulatory action, an official acknowledgment of a serious and unexplained adverse effect. While it did not identify the immune mechanism, it served as a stark official caution that EPO was not simply a benign factor in the context of cancer. This historical warning now gains profound new context, as the Stanford research provides the long-sought mechanistic explanation for that observed danger.
Dr. Engleman’s Scientific Enthusiasm: Dr. Edgar Engleman’s quotes reflect the profound impact of this discovery on the scientific community. His statement, "This is a fundamental breakthrough in our understanding of how the immune system is turned off and on in cancer," underscores the paradigm-shifting nature of the findings. The excitement is palpable, stemming from the realization that a well-known protein has a completely new and critical function in disease. His expressed hope that "treatments that target the mechanism we uncovered will quickly move forward to human trials" is a clear official call to action for the clinical translation of these findings. This sentiment is echoed in his amazement: "I continue to be amazed by this finding… I’m very optimistic that this discovery will lead to powerful new cancer therapies."
Future Clinical Development: The researchers themselves are now actively designing therapeutic strategies targeting EPO signaling in human cancers. This represents the most immediate "official response" to their own discovery. Their work, including the intellectual property filed (PCT/US2023/063997, entitled "EPO receptor agonists and antagonists"), signals a committed move towards clinical application. The involvement of pharmaceutical company ImmunEdge Inc., co-founded by Dr. Chiu and with Dr. Engleman as a founder, shareholder, and board member, further illustrates the concerted effort to translate this basic science into tangible patient benefits. The National Institutes of Health (NIH) grants (R01CA262361, P01CA244114, U54CA2745115, P01HL149626) that funded this study represent a crucial "official response" from a major governmental funding body, validating the scientific merit and potential impact of the research from its inception.
Implications: A New Era for Cancer Immunotherapy
The discovery of EPO’s critical role in dampening the anti-cancer immune response carries vast implications, promising to usher in a new era for cancer immunotherapy and potentially transforming the treatment landscape for millions of patients.
Expanding Immunotherapy Efficacy: Perhaps the most immediate and impactful implication is the potential to extend the benefits of immune checkpoint inhibitors to a much broader patient population. Current immunotherapies, while revolutionary, are effective in only a subset of cancers, largely those characterized by "hot" tumors. The majority of solid tumors, including common and deadly cancers of the liver, pancreas, colon, breast, and prostate, remain largely resistant. This research provides a clear strategy to convert these "cold" tumors into "hot" ones, thereby sensitizing them to existing anti-PD-1/PD-L1 therapies. This could unlock effective treatment options for many patients who currently have limited choices.
Novel Therapeutic Avenues: The study identifies two primary, complementary therapeutic strategies:
- Non-specific EPO Targeting: Reducing overall EPO levels in the body could theoretically remove the immunosuppressive signal. While this approach carries the risk of inducing anemia, Dr. Engleman speculates that for an effective cancer therapy, this might be an "acceptable trade-off," given the severity of the disease. This could involve drugs that inhibit EPO production or neutralize circulating EPO.
- Selective Macrophage EPOR Blockade: A more precise approach would be to selectively block the EPO receptors (EPOR) specifically on the surface of macrophages within the tumor microenvironment. This strategy aims to prevent macrophages from switching to their immunosuppressive state without affecting EPO’s beneficial role in red blood cell production elsewhere in the body, potentially mitigating the anemia side effect. This precision targeting could lead to highly specific and potent anti-cancer drugs.
A Paradigm Shift in Understanding Cancer Immunity: This discovery fundamentally alters our understanding of how the tumor microenvironment orchestrates immune evasion. It highlights that seemingly unrelated physiological processes, such as red blood cell regulation, can have profound and unexpected implications for cancer immunity. This encourages researchers to re-examine other established biological pathways for hidden immunomodulatory functions, potentially uncovering further therapeutic targets. The findings demonstrate the complex interplay between hypoxia, tumor cells, and immune cells, offering a more nuanced view of tumor survival strategies.
Broader Applicability Across Cancer Types: While the initial work was conducted in liver cancer models, the strong indications from human cancer databases suggest that this mechanism is likely applicable to many types of human cancers where high EPO/EPOR levels correlate with poor prognosis. This broad applicability is a significant implication, as it means the therapeutic strategies developed based on this research could benefit patients with a wide range of solid tumors currently considered refractory to immunotherapy.
Accelerated Drug Development: The identification of a well-characterized protein like EPO as a target could potentially accelerate drug development. Pharmaceutical companies already have experience with EPO-related molecules, and the pathway itself is well-understood. This foundational knowledge could shorten the preclinical and clinical development timelines for new EPO-targeting cancer therapies. The collaboration with ImmunEdge Inc. already indicates this translational momentum.
Improved Patient Outcomes and Quality of Life: Ultimately, the most significant implication is the potential for improved patient outcomes. By making "cold" tumors "hot" and sensitive to immunotherapy, patients could experience higher response rates, prolonged survival, and potentially cures for cancers that are currently devastating. This would translate into a dramatic improvement in quality of life for cancer patients and their families.
New Avenues for Diagnostic and Prognostic Markers: Beyond therapy, the findings could lead to the development of new diagnostic or prognostic markers. Measuring EPO or EPOR levels in tumors or in the blood could help identify patients who are likely to have "cold" tumors and therefore benefit most from EPO-targeting therapies, allowing for personalized treatment strategies.
The journey of erythropoietin has come full circle, from a life-saving blood stimulant to a cautionary tale in oncology, and now, finally, to a promising new target in the fight against cancer. This remarkable scientific achievement by Dr. Engleman, Dr. Chiu, and their colleagues at Stanford University, with contributions from the New York Blood Center, has not only solved a long-standing mystery but has also illuminated a powerful new path forward in cancer therapy. The scientific community, patients, and clinicians alike will eagerly await the rapid progression of these promising findings towards human trials.
About the Author
